Karamitros C, Somody C, Agnello G, Rowlinson S
Front Bioeng Biotechnol. 2022; 9:793985.
PMID: 34976980
PMC: 8718881.
DOI: 10.3389/fbioe.2021.793985.
Almandil N, Taha M, Farooq R, Alhibshi A, Ibrahim M, Anouar E
Molecules. 2019; 24(6).
PMID: 30871147
PMC: 6471342.
DOI: 10.3390/molecules24061002.
Iwai T, Harada Y, Saeki H, Oki E, Maehara Y, Yonemitsu Y
Oncotarget. 2018; 9(25):17620-17630.
PMID: 29707135
PMC: 5915143.
DOI: 10.18632/oncotarget.24811.
De Clercq E
Med Res Rev. 2009; 31(1):118-60.
PMID: 19844936
PMC: 7168424.
DOI: 10.1002/med.20179.
Lu H, Klein R, Schwartz E
Clin Cancer Res. 2009; 15(16):5136-44.
PMID: 19671868
PMC: 2777687.
DOI: 10.1158/1078-0432.CCR-08-3203.
The cytosol activity of thymidine phosphorylase in endometrial cancer.
Miszczak-Zaborska E, Kubiak R, Bienkiewicz A, Bartkowiak J
J Exp Clin Cancer Res. 2008; 27:64.
PMID: 18986516
PMC: 2588563.
DOI: 10.1186/1756-9966-27-64.
The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.
Nimmagadda S, Shields A
Cancer Metastasis Rev. 2008; 27(4):575-87.
PMID: 18512023
PMC: 3086165.
DOI: 10.1007/s10555-008-9148-5.
Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.
Silletti S, Paku S, Raz A
Pathol Oncol Res. 2008; 3(3):230-54.
PMID: 18470736
DOI: 10.1007/BF02899927.
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
Miyake K, Imura S, Yoshizumi T, Ikemoto T, Morine Y, Shimada M
Int J Clin Oncol. 2007; 12(2):111-9.
PMID: 17443278
DOI: 10.1007/s10147-006-0634-x.
Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.
Temmink O, Hoebe E, van der Born K, Ackland S, Fukushima M, Peters G
Br J Cancer. 2007; 96(2):231-40.
PMID: 17242697
PMC: 2360012.
DOI: 10.1038/sj.bjc.6603549.
Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug design.
El Omari K, Bronckaers A, Liekens S, Perez-Perez M, Balzarini J, Stammers D
Biochem J. 2006; 399(2):199-204.
PMID: 16803458
PMC: 1609907.
DOI: 10.1042/BJ20060513.
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.
Lassmann S, Hennig M, Rosenberg R, Nahrig J, Schreglmann J, Krause F
Int J Colorectal Dis. 2005; 21(3):238-47.
PMID: 16132996
DOI: 10.1007/s00384-005-0767-9.
The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression.
Akiyama S, Furukawa T, Sumizawa T, Takebayashi Y, Nakajima Y, Shimaoka S
Cancer Sci. 2004; 95(11):851-7.
PMID: 15546501
PMC: 11159696.
DOI: 10.1111/j.1349-7006.2004.tb02193.x.
Targeted deletion of both thymidine phosphorylase and uridine phosphorylase and consequent disorders in mice.
Haraguchi M, Tsujimoto H, Fukushima M, Higuchi I, Kuribayashi H, Utsumi H
Mol Cell Biol. 2002; 22(14):5212-21.
PMID: 12077348
PMC: 139774.
DOI: 10.1128/MCB.22.14.5212-5221.2002.
Capecitabine: preclinical pharmacology studies.
Ishitsuka H
Invest New Drugs. 2000; 18(4):343-54.
PMID: 11081570
DOI: 10.1023/a:1006497231579.
Variations in the expression of platelet-derived endothelial cell growth factor in human colorectal polyps.
Enomoto T, Kuranami M, Kakita A
Surg Today. 2000; 30(8):711-7.
PMID: 10955734
DOI: 10.1007/s005950070082.
Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases.
Konda R, Sato H, Sakai K, Sato M, Orikasa S, Kimura N
Am J Pathol. 1999; 155(5):1587-97.
PMID: 10550316
PMC: 1866986.
DOI: 10.1016/S0002-9440(10)65475-2.
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
Evrard A, Cuq P, Ciccolini J, Vian L, Cano J
Br J Cancer. 1999; 80(11):1726-33.
PMID: 10468288
PMC: 2363120.
DOI: 10.1038/sj.bjc.6690589.
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
Stevenson D, COLLINS W, Farzaneh F, Hata K, Miyazaki K
Am J Pathol. 1998; 153(5):1573-8.
PMID: 9811349
PMC: 1853412.
DOI: 10.1016/S0002-9440(10)65745-8.
Effects of platelet-derived endothelial cell growth factor/thymidine phosphorylase, substrate, and products in a three-dimensional model of angiogenesis.
Stevenson D, Milligan S, COLLINS W
Am J Pathol. 1998; 152(6):1641-6.
PMID: 9626068
PMC: 1858429.